Trial · NCT06855823
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NCT06855823, Phase 1, Phase 2, Recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL. Trials, record NCT06855823. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06855823
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
- NCT number
- NCT06855823
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
- Interventions
- Golicitinib combined with Pomadomide
- First posted
- 2025-03-04
- Last updated
- 2025-03-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) in Phase I | Up to approximately 1 month | Incidence of dose-limiting toxicities during the first cycle of treatment and determination of the maximum tolerated dose of pomalidomide in combination with golidocitinib. |
| Primary | Objective Response Rate (ORR) in Phase II | Up to approximately 24 months | The proportion of patients achieving either complete response (CR) or partial response (PR) as per the 2014 Lugano criteria. |
| Secondary | Objective Response Rate (ORR) after 4 cycles (Lugano 2014) | Up to approximately 2 years | ORR is defined as the proportion of subjects achieving complete response (CR) or partial response (PR). |
| Secondary | Complete Response Rate (CRR) after 4 cycles (Lugano 2014) | Up to approximately 2 years | CRR is calculated as the percentage of the sum of the number of patients in complete remission (CR) and complete remission without confirmation (CRu) to the total number of patients in the full analysis set. |
| Secondary | Duration of Response (DOR) | Up to approximately 2 years | DOR is defined as the time from the first documentation of confirmed response (CR or PR) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. |
| Secondary | Progression-Free Survival (PFS) | Up to approximately 2 years | PFS is defined as the time from the first dose of investigational products until documentation of PD or death due to any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | Up to approximately 2 years | OS is defined as the time from the first dose of investigational products until death due to any cause. |
| Secondary | Incidence and Severity of Adverse Events (AEs) | Up to approximately 2 years | The incidence and severity of AEs are assessed to evaluate the safety profile of golidocitinib combined with pomalidomide. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06855823
GET https://conductscience.org/api/trials/v1/NCT06855823/registered